论文部分内容阅读
Background Apo A1 as a key part of high density lipoprotein(HDL) has an important role in lipid metabolism. Diabetic patients often have disorders of lipid metabolism and apo A1 reduction. However, the benefits of fenofibrate in diabetes remain unclear as it increases the expression of apo A1. Methods A total of 80 patients with type 2 diabetes(40 mens, 40 femal) were collected in First Affiliated Hospital of Gannan Medical University. According to the level of apo A1, subjects were assigned to apo A1 normal experimental group(A1 group, 20cases) and apo A1 normal control group(A2 group, 20 cases), apo A1 reduction experimental group(A3 group, 20cases), apo A1 reduction control group(A4 group 20 cases). The control group was only given conventional hypoglycemic therapy; Experimental group was given conventional hypoglycemic therapy and fenofibrate 200 mg/d treatment. The blood lipid and glucose were monitored after two-months treatment. Result After treatment with fenofibrate, the level of apo A1 in the experimental group was increased(A1 1.28 ± 0.05 vs. 1.39 ± 0.06; A3 0.81± 0.08 vs. 1.00 ± 0.11) and the lipid disorder was improved(A1 group TC 5.58 ± 0.32 vs. 5.19 ± 0.34, P = 0.01;TG 2.69 ± 0.07 vs. 2.52 ± 0.11, P = 0.013; HDL 1.30 ± 0.09 vs. 1.38 ± 0.05, P = 0.04; LDL 2.28 ± 0.15 vs. 2.19 ±0.15, P < 0.01; A3 group TC 5.88 ± 0.11 vs. 5.62 ± 0.16, P < 0.01; TG 2.92 ± 0.18 vs. 2.67 ± 0.28, P < 0.01; HDL1.14 ± 0.19 vs. 1.22 ± 0.16, P < 0.01; LDL 2.48 ± 0.13 vs. 2.39 ± 0.11, P = 0.037). The blood glucose was not changed in all treatment groups. Conclusion Fenofibrate can increase the level of apo A1 and improve lipid metabolism in type 2 diabetic patients, without affecting blood glucose.
Background Apo A1 as a key part of high density lipoprotein (HDL) has an important role in lipid metabolism. Diabetic patients often have disorders of lipid metabolism and apo A1 reduction. However, the benefits of fenofibrate in diabetes remain unclear as it increases the expression of apo A1. Methods A total of 80 patients with type 2 diabetes (40 mens, 40 femal) were collected in First Affiliated Hospital of Gannan Medical University. According to the level of apo A1, subjects were assigned to apo A1 normal experimental group ( A1 group, 20cases) and apo A1 normal control group (A2 group, 20 cases), apo A1 reduction experimental group (A3 group, 20cases), apo A1 reduction control group (A4 group 20 cases). The control group was only given conventional The hypoglycemic therapy; Experimental group was given conventional hypoglycemic therapy and fenofibrate 200 mg / d treatment. The blood lipid and glucose was monitored after two-months treatment. Result After treatment with fenofibrate, the level of apo A1 in the experimental group was increased (A1 1.28 ± 0.05 vs. 1.39 ± 0.06; A3 0.81 ± 0.08 vs. 1.00 ± 0.11) and the lipid disorder was improved (A1 group TC 5.58 ± 0.32 vs. 5.19 ± 0.34, P = 0.01; TG 2.69 ± 0.07 vs. 2.52 ± 0.11, P = 0.013; HDL 1.30 ± 0.09 vs. 1.38 ± 0.05, P = 0.04; LDL 2.28 ± 0.15 vs. 2.19 ± 0.15, P <0.01 A3 group TC 5.88 ± 0.11 vs. 5.62 ± 0.16, P <0.01; TG 2.92 ± 0.18 vs. 2.67 ± 0.28, P <0.01; HDL 1.14 ± 0.19 vs. 1.22 ± 0.16, P <0.01; LDL 2.48 ± 0.13 vs. 2.39 ± 0.11, P = 0.037). The blood glucose was not changed in all treatment groups. Conclusion Fenofibrate can increase the level of apo A1 and improve lipid metabolism in type 2 diabetic patients, without affecting blood glucose.